Introduction {#S1}
============

Activated PI3Kδ syndrome (APDS) is a primary immunodeficiency (PID) characterized by recurrent respiratory tract infections, chronic Epstein Barr virus and cytomegalovirus infections, lymphoproliferation, increased lymphoma susceptibility, and poor antibody production ([@B1]--[@B4]). Heterozygous gain-of-function mutations in *PIK3CD*, which encodes the catalytic subunit p110δ of phosphoinositide 3-kinase (PI3K), have been identified in patients with APDS1 ([@B1], [@B3]). Subsequent studies have demonstrated that a heterozygous mutation in *PIK3R1* encoding p85α, a regulatory subunit of PI3K, is responsible for APDS2: a PID with similar clinical manifestations to APDS1 ([@B2], [@B4]). Moreover, a patient with a heterozygous loss-of-function mutation in *PTEN*, which encodes phosphatase and tensin homolog and is associated with PTEN hamartoma tumor syndrome (PHTS), was recently reported to develop APDS-like immunodeficiency (APDS-L) with incomplete penetrance ([@B5], [@B6]).

Phosphoinositide 3-kinases convert phosphatidylinositol 3,4-triphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) and are involved in cellular functions including proliferation, differentiation, survival, and trafficking ([@B7], [@B8]). Both p110δ and p85α belong to class IA PI3Ks and have an essential role in the differentiation, development, and functions of several distinct stages of B- and T-lymphocytes ([@B7], [@B8]). They also have an important role in the antibody maturation process by regulating immunoglobulin class-switch recombination and plasma cell differentiation ([@B9]). When stimulated, PIP3 recruits AKT to the plasma membrane where AKT is activated *via* phosphorylation by PDK1 and mTORC2 ([@B7], [@B8]). In contrast, PTEN antagonizes PI3Ks by catalytic dephosphorylation of PIP3 to PIP2 ([@B10]). The recent identification of APDS1 and APDS2 (APDSs) and APDS-L revealed that the hyperactive PI3K/AKT signaling affects the immune system in humans, leading to the development of PID.

Here, we investigated four unrelated Japanese patients with APDS2 caused by a heterozygous mutation in *PIK3R1*. Activated T cells from the patients showed enhanced phosphorylation of Ser473 of AKT (pAKT) consistent with findings in previous reports ([@B2], [@B4]). We next investigated the status of pAKT using peripheral blood mononuclear cells (PBMCs) isolated from patients and analyzed by flow cytometry. We observed that circulating CD19^+^ B cells from APDS2 patients, but not other cell populations, showed enhanced pAKT. This finding was similarly detected in circulating CD19^+^ B cells from patients with APDSs or APDS-L, but not from healthy controls, common variable immunodeficiency (CVID) patients, or hyper IgM syndrome (HIGM) patients due to CD40L deficiency. Therefore, enhanced pAKT signaling in circulating CD19^+^ B cells was considered a specific finding in patients with APDSs or APDS-L. Furthermore, by focusing on CD10^+^CD19^+^ immature B cells, this method allowed us to distinguish APDSs and APDS-L patients from healthy controls and patients with CVID or HIGM (CVID/HIGM). This flow-cytometry-based assay of PI3K activity enabled the discrimination analysis of identified mutations in *PIK3CD, PIK3R1*, or *PTEN*. It may also serve as a rapid diagnostic method to discriminate APDSs and APDS-L patients from other PID.

Materials and Methods {#S2}
=====================

Cases {#S2-1}
-----

We investigated four unrelated Japanese patients with APDS2 who were involved in a previous international survey (P13, P14, P19, and P26 in the previous report) ([@B11]). The detailed clinical manifestations of those patients are available in Materials and Methods in Supplementary Material. All of the patients carried heterozygous germline mutations in *PIK3R1* (Figure S1 in Supplementary Material). The identification of *PIK3R1* mutation was performed by a candidate gene approach in P4. For the other three patients, the mutations were identified by whole exome sequencing and were confirmed by Sanger sequencing. The identified mutations were 1425 + 2 T \> A (P1), 1300−1 G \> C (P2), 1425 + 1 G \> C (P3), and 1425 + 1 G \> T (P4). The *PIK3R1* mutations identified in P3 and P4 were previously shown to be pathogenic mutations ([@B2], [@B4]).

We included four CVID patients, aged 33 (P5), 36 (P6), 17 (P7), and 30 (P8) years, whose genetic causes have not been identified (detailed in Materials and Methods in Supplementary Material). The absence of pathogenic mutations in *PIK3CD, PIK3R1*, and *PTEN* was confirmed in those patients. We also included one HIGM patient due to CD40L deficiency (P9) who was 41 years old (detailed in Materials and Methods in Supplementary Material).

Immunoblot Analysis {#S2-2}
-------------------

CD3^+^ T cells and CD19^+^ B cells were separated from PBMCs using the IMag™ Cell Separation System (BD Biosciences, San Jose, CA, USA). The separated cells were then subjected to immunoblot analysis using the following antibodies: anti-AKT antibody (Cell Signaling Technology, Danvers, MA, USA), anti-phospho-AKT (Ser473) antibody (Cell Signaling Technology), and ß-actin (SIGMA-ALDRICH, Saint Louis, MO, USA).

Preparation of Activated T Cells {#S2-3}
--------------------------------

Activated T cells were derived from PBMCs according to a previous report ([@B2]). Briefly, PBMCs were cultured with 1 × 10^6^ cells per mL in RPMI 1640 GlutaMax supplemented with 10% human AB serum, penicillin and streptomycin, PMA (1 µmol/L), and ionomycin (20 ng/mL) for 2 days. The cells were then separated by Lymphoprep density-gradient centrifugation and washed twice with RPMI 1640 GlutaMax. Then, they were cultured in RPMI 1640 GlutaMax supplemented with 10% human AB serum and IL-2 (100 IU/mL) for 16--24 h.

B-Cell Stimulation {#S2-4}
------------------

For B-cell stimulation, PBMCs were purified by Lymphoprep density-gradient centrifugation and incubated at 1 × 10^6^ cells per mL in RPMI 1640 GlutaMax supplemented with 10% human AB serum, penicillin, and streptomycin. The cells were stimulated with CD40L (1 µg/mL) and IL-4 (20 ng/mL) for 30 min. They were then harvested and subjected to flow-cytometry analysis of AKT phosphorylation.

Flow-Cytometry Analysis of AKT Phosphorylation {#S2-5}
----------------------------------------------

Peripheral blood mononuclear cells from APDS1 (four patients), APDS2 (four patients), APDS-L (four patients), CVID (four patients), HIGM (one patient), and 24 adult healthy controls were subjected to flow-cytometry analysis. We assessed pAKT at Ser473 by flow cytometry as follows. PBMCs were suspended at a density of 1 × 10^6^ cells/μL in serum-free RPMI with or without 10 µM of 110δ inhibitor (IC87114) in the presence of FITC-conjugated anti-CD19 (HIB19) (BD Biosciences). The cells were incubated for 20 min at 37°C and washed twice. They were fixed and permeabilized according to the BD Phosflow protocol (protocol III). They were then stained and subjected to flow cytometry. The following antibodies were used for staining: Alexa Fluor 647-conjugated anti-phospho AKT (Ser473) (D9E) (Cell Signaling Technology), FITC-conjugated anti-CD19 (BD Biosciences), PE-conjugated anti-CD3 (UCHT1) (BD Biosciences), PE-conjugated anti-CD14 (Mφ97) (BD Biosciences), or FITC-conjugated anti-CD56 (C5.9) (SIGMA-ALDRICH), PE-conjugated CD16 (3G8) (BD Biosciences), and PerCP-Cy 5.5-conjugated anti-CD10 (HI10a) (BD Biosciences). Negative selection of B cells from PBMCs was performed using Pan B-Cell Isolation Kit, human (Miltenyi Biotec Inc., Auburn, CA, USA).

Statistical Analysis {#S2-6}
--------------------

Receiver operating characteristic (ROC) curves were created with Easy R (EZR) software available online (<http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html>). EZR is statistical software and is based on R and R commander. EZR enables the application of statistical functions ([@B12]). Statistical hypotheses were tested using a two-tailed *t*-test. A *p* value \< 0.05 was considered significant.

Results {#S3}
=======

Mutation Analysis of Patients With APDS2 {#S3-1}
----------------------------------------

We found a splice site mutation at the + 2 position following exon 10 (Figure [1](#F1){ref-type="fig"}A). Amplification of cDNA showed an aberrant, faster migrating band suggesting a deletion (Figure [1](#F1){ref-type="fig"}B). Sanger sequencing demonstrated a deletion of exon 10 in the patient (Figure [1](#F1){ref-type="fig"}C) but not in his mother (Figure [1](#F1){ref-type="fig"}D). Thus, we confirmed that the identified *PIK3R1* mutations in P1, as well as the other two mutations, are pathogenic mutations, leading to the skipping of exon 10 with a deletion of amino acid residues 434--475 of p85α (Figure [1](#F1){ref-type="fig"}B). The former diagnosis of four patients with APDS2 was CVID (P1), HIGM (P2 and P4), and IgG subclass deficiency (P3). The identified mutations in PIK3R1 were *de novo* in Family B, C, and D, since we found no asymptomatic carrier in a familial study. In order to determine the mechanism of disease in patients with APDS2, we focused on pAKT function associated with PI3K signaling.

![The effect of splice site mutation identified in P1. **(A)** A germline heterozygous mutation, **(B)** 1425 + 2 T \> A, in *PIK3R1* was identified by whole exome sequencing and confirmed by Sanger sequencing. **(C)** mRNA was extracted from peripheral blood mononuclear cells from P1 and his mother. Complementary DNA was then synthesized to assess the significance of the nucleotide substitution, 1425 + 2 T \> A, on splicing. **(C,D)** The RT-PCR fragment was cloned into a pGEM-T easy vector. Loss of exon 10 in patient **(C)** but not mother **(D)** was revealed by Sanger sequencing.](fimmu-09-00568-g001){#F1}

Circulating CD19^+^ B Cells From Patients With APDSs or APDS-L Showing Enhanced pAKT Signaling {#S3-2}
----------------------------------------------------------------------------------------------

Enhanced pAKT signaling associated with hyperactive PI3K signaling is a common finding in patients with APDSs ([@B1]--[@B4]). We first assessed the status of pAKT in fresh (non-cultured) PBMCs from APDS2 patients by flow cytometry. There was no obvious difference in the level of pAKT in CD3^+^ T cells, CD16^+^CD56^+^ natural killer (NK) cells, and CD14^+^ monocytes between APDS2 patients and healthy controls (Figure [2](#F2){ref-type="fig"}A). In P1's CD14^+^ monocytes, pAKT was slightly enhanced in the absence of p110δ inhibitor treatment compared with untreated, but this difference was non-significant. In contrast, CD19^+^ B cells from the APDS2 patient (P1) had significantly higher levels of pAKT compared with those from healthy controls. By treating them with a p110δ inhibitor, the enhancement of pAKT observed in CD19^+^ B cells was normalized. In order to exclude the possibility of stimulation of B cells by staining them with anti-CD19 antibody, we confirmed this finding by analyzing circulating B cells separated by negative selection (Figure [2](#F2){ref-type="fig"}B).

![Flow-cytometry-based AKT phosphorylation (pAKT) assay of PMBCs. **(A)** The level of pAKT in the presence or absence of p110δ inhibitor treatment was assessed by flow cytometry in total peripheral blood mononuclear cells (PBMCs), CD3^+^ T cells, CD14^+^ monocytes, and CD16^+^CD56^+^ natural killer cells from activated PI3Kδ syndrome 2 (APDS2) (P1), common variable immunodeficiency (CVID) (P8), or hyper IgM syndrome (HIGM) (P9). The number of events analyzed was \>5,000. Red bold line: no treatment and black dotted line: p110δ inhibitor treatment. **(B)** The level of pAKT in negatively selected B cells from PBMCs from P1 and one healthy control was compared with pAKT in CD19^+^ B cells. Red solid line: no treatment and black dotted line: p110δ inhibitor treatment. **(C)** A summary of difference in mean fluorescence intensity of whole lymphocytes derived from 24 adult healthy controls or all of the patients with APDS2 or CVID/HIGM. There is no statistical significant among this three groups (control vs. CVID; *p* = 0.24, APDS2 vs. CVID; *p* = 0.13, and control vs. APDS2; *p* = 0.52).](fimmu-09-00568-g002){#F2}

We measured the mean fluorescence intensity (MFI) of pAKT in the presence or absence of p110δ inhibitor treatment by flow cytometry. We then evaluated enhanced pAKT signaling by calculating the difference in MFI (ΔMFI) of pAKT in CD19^+^ B cells as the difference between MFI (the absence of p110δ inhibitor) and MFI (the presence of p110δ inhibitor). CD19^+^ B cells from APDS2 patients had significantly higher ΔMFI of pAKT than those from healthy controls or CVID/HIGM patients, although ΔMFI of pAKT in whole lymphocytes was almost at the same levels among all individuals (Figures [2](#F2){ref-type="fig"}C and [3](#F3){ref-type="fig"}D). The protein expression of total AKT in CD19^+^ B cells from an APDS2 patient (P1) was equivalent to that in healthy controls (Figure [3](#F3){ref-type="fig"}A). The result was consistent with the previous studies showing the normal AKT protein expression in APDSs and APDS-L patients ([@B1]--[@B4], [@B6]). The enhancement of pAKT in CD19^+^ B cells was confirmed by immunoblotting (Figure [3](#F3){ref-type="fig"}B; Figure S2 in Supplementary Material). In contrast, there was no difference in the level of pAKT in CD3^+^ T cells (Figure [3](#F3){ref-type="fig"}B; Figure S2 in Supplementary Material).

![Enhanced AKT phosphorylation (pAKT) in CD19^+^ B cells from patients with activated PI3Kδ syndromes (APDSs) or APDS-like (APDS-L). **(A)** Total AKT expression in CD19^+^ B cells from APDS2 patients (P1) was measured by flow-cytometry. Red bold line: activated PI3Kδ syndrome 2 (APDS2) patient and black dotted line: healthy control. **(B)** The phosphorylation and protein expression of AKT was investigated by immunoblotting. **(C)** pAKT (pS473) in the presence of p110δ inhibitor was analyzed by flow cytometry in CD19^+^ B cells from healthy controls and patients with APDS1, APDS2, or APDS-L, CVID/HIGM. The number of events analyzed was \>5,000. **(D)** A summary of difference in mean fluorescence intensity of CD19^+^ B cells derived from healthy controls or patients with APDS1 (four patients), APDS2 (P1, P2, P3, and P4), APDS-L (four patients), or CVID/HIGM (P5, P6, P7, P8, and P9). \**p* \< 0.05 and \*\**p* \< 0.01.](fimmu-09-00568-g003){#F3}

We next tested the hypothesis that enhanced pAKT signaling in CD19^+^ B cells is a common finding of patients with hyperactive PI3K signaling. We analyzed PBMCs from patients with APDS1 or APDS-L carrying a heterozygous mutation in *PIK3CD* or *PTEN*, respectively. As expected, CD19^+^ B cells from APDS1 and APDS-L showed significantly higher levels of pAKT compared with healthy controls and CVID/HIGM patients (Figure [3](#F3){ref-type="fig"}C). As above, the enhancement of pAKT observed in these patients was normalized by treatment with a p110δ inhibitor. Similar to the results obtained from patients with APDS2, the level of pAKT was normal in CD3^+^ T cells, CD16^+^CD56^+^ NK cells, and CD14^+^ monocytes from patients with APDS1 or APDS-L (data not shown). However, CD19^+^ B cells and other cell populations from patients with CVID and HIGM had normal levels of pAKT expression (Figure [2](#F2){ref-type="fig"}A). Curiously, CD19^+^ B cells from APDS2 patients had the highest ΔMFI of pAKT among all APDSs patients (Figure [3](#F3){ref-type="fig"}D), followed by elevated ΔMFI of pAKT in APDS-L patients observed as significantly higher than healthy controls and CVID/HIGM patients (Figure [3](#F3){ref-type="fig"}D). In addition, higher levels of pAKT were also observed in CD19^+^ B cells from cryopreserved PBMCs (Figures S3A,B in Supplementary Material). Therefore, the enhancement of pAKT in CD19^+^ B cells was considered to be a specific finding among patients with APDSs and APDS-L.

Enhanced pAKT Signaling in Activated T Cells From APDS2 Patients {#S3-3}
----------------------------------------------------------------

The previous study showed the enhancement of pAKT signaling in activated T cells from APDSs ([@B1]--[@B4]). We next investigated pAKT levels in activated T cells derived from PBMCs by flow cytometry. CD3^+^CD4^+^ and CD3^+^CD8^+^-activated T cells from P1 showed enhanced pAKT compared with those from healthy controls (Figure [4](#F4){ref-type="fig"}A). The enhancement of pAKT observed in P1 was normalized by treating cells with a p110δ inhibitor. The result was consistent with previous studies that investigated activated T cells from patients with APDSs ([@B1]--[@B4]). Thus, we confirmed the enhancement of pAKT in activated T cells from APDS2 patients by flow cytometry. Next, we stimulated B cells with CD40L and IL-4 and investigated the level of pAKT. Following stimulation with CD40L and IL-4, we observed the enhancement of pAKT in CD19^+^ B cells from APDS2 patient and healthy control (Figure [4](#F4){ref-type="fig"}B). However, this difference became less striking after CD40L and IL-4 stimulation.

![**(A)** AKT phosphorylation (pAKT) expression in activated T cells, **(B)** pAKT expression CD19^+^ B cells stimulated with CD40L and IL-4. **(A)** The level of pAKT in T cells was assessed by flow cytometry in activated PI3Kδ syndrome 2 patient (P1) and healthy controls (representative result from two controls is shown). The total number of events analyzed was 2,000. Red bold line: no treatment and black dotted line: p110δ inhibitor treatment. **(B)** pAKT expression in CD19^+^ B cells from (P1) and healthy control following stimulation with CD40L and IL-4. Blue line: isotype control, black and red solid line: no treatment, and black and red dot line: CD40L and IL-4 treatment.](fimmu-09-00568-g004){#F4}

The Enhancement of pAKT in Patients With APDSs Pronounced in CD10^+^CD19^+^ Immature B Cells {#S3-4}
--------------------------------------------------------------------------------------------

Phosphoinositide 3-kinase signaling has important roles in differentiation, development, and functions in several distinct stages of B and T cells ([@B7], [@B8]). Patients with APDS1, APDS2, or APDS-L had increased numbers of transitional B cells in the peripheral blood, possibly reflecting the pivotal role of PI3K signaling in the differentiation of B cells ([@B1]--[@B5]). In our study, APDS2 patients had increased numbers of transitional B cells in peripheral blood consistent with previous studies (Figure S4 in Supplementary Material). We investigated pAKT levels in CD19^+^ B cells by dividing them into three developmental stages: (i) total CD19^+^ B cells, (ii) CD10^−^CD19^+^ mature B cells, and (iii) CD10^+^CD19^+^ immature B cells (corresponding to transitional B cells) by flow cytometry (Figure S5 in Supplementary Material). CD19^+^ B cells at all three developmental stages from patients with APDS1, APDS2, or APDS-L had higher levels of pAKT compared with healthy controls. Surprisingly, the enhancement of pAKT was most pronounced in CD10^+^CD19^+^ immature B-cell populations from APDS1, APDS2, or APDS-L patients (Figure [5](#F5){ref-type="fig"}). This finding was confirmed by CD10^+^ negatively selected B cells, controlling for the potential B-cell activation by anti-CD19 antibody staining (Figure S6 in Supplementary Material).

![Enhanced AKT phosphorylation (pAKT) in activated PI3Kδ syndrome 2 (APDS2) patients was pronounced in a flow-cytometry assay of CD10^+^CD19^+^ B cells. **(A,B)** The enhancement of pAKT observed in CD19^+^ B cells was further investigated by separating them into CD10^+^CD19^+^ immature B cells and CD10^−^CD19^+^ mature B cells from P2 (representative histogram of three experiments) **(A)** and healthy controls **(B)**. The number of events analyzed was \>5,000. As an exception, CD10^+^CD19^+^ immature B cells analyzed in healthy control were 800 events. Red solid line: no treatment and black dotted line: p110δ inhibitor treatment. **(C,D,E)** A summary of difference in mean fluorescence intensity of CD19^+^ B cells **(C)**, CD10^−^CD19^+^ mature B cells **(D)**, and CD10^+^CD19^+^ immature B cells **(E)** from healthy controls or patients with APDS1 (three patients), APDS2 (P1, P2, and P4), or APDS-like (APDS-L) (three patients). \**p* \< 0.05 and \*\**p* \< 0.01.](fimmu-09-00568-g005){#F5}

Establishment of a Flow-Cytometry-Based Rapid Discrimination Assay Based on the Enhancement of PI3K Signaling {#S3-5}
-------------------------------------------------------------------------------------------------------------

We found that CD19^+^ B cells from APDSs or APDS-L patients had significantly higher levels of pAKT than healthy controls and patients with CVID or HIGM. The higher level of pAKT observed in these patients was normalized by treating the cells with a p110δ inhibitor. This discovery led us to the idea that the detection of enhanced pAKT signaling in CD19^+^ B cells is a useful diagnostic tool for the rapid discrimination study of suspected APDS patients. CD19^+^ B cells from patients with APDS2 had the highest ΔMFI of pAKT among all APDSs or APDS-L patients. In contrast, elevated ΔMFI of pAKT in CD19^+^ B cells was modest in APDS-L patients (Figure [3](#F3){ref-type="fig"}D). We next analyzed the ΔMFI of pAKT in CD10^−^CD19^+^ and CD10^+^CD19^+^ B cells. As expected, the ΔMFI of pAKT was high in both B-cell populations from APDSs or APDS-L patients when compared with those from healthy controls (Figures [5](#F5){ref-type="fig"}C--E). The high ΔMFI of pAKT was emphasized in the analysis of CD10^+^CD19^+^ immature B cells (Figure [5](#F5){ref-type="fig"}E). Moreover, if we focused on CD10^+^CD19^+^ immature B cells, there was no overlap in the value of ΔMFI between APDSs and APDS-L patients and the other populations including healthy controls and CVID/HIGM patients. This finding strongly suggests that the flow-cytometry-based assay to measure the ΔMFI of pAKT can be used as a discrimination assay to detect the enhancement of PI3K activity in patients with APDSs and APDS-L (flow chart is shown in Figure S7 in Supplementary Material).

Cutoff Value of ΔMFI of pAKT Segregating APDSs and APDS-L Patients {#S3-6}
------------------------------------------------------------------

We created an ROC curve based on the results of the ΔMFI of pAKT obtained from the analysis of CD19^+^ B cells. We used EZR for statistical analysis and set up the cutoff value of ΔMFI of pAKT as 117. This cutoff value allows the segregation of APDSs and APDS-L patients from healthy controls or CVID patients with 100% sensitivity and 96.0% specificity (Figure S8 in Supplementary Material). The area under the curve was 0.996 (95% confidence interval 0.986−1.000) ([@B12]).

Discussion {#S4}
==========

Here, we investigated four Japanese cases with APDS2 carrying a heterozygous mutation in *PIK3R1*. Elkaim et al. recently summarized the clinical and immunological aspects of 36 genetically diagnosed APDS2 patients and revealed that recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%) were the most common clinical features ([@B11]). Malignant diseases were identified in 28% of patients, most of them were B-cell lymphomas. Laboratory findings showed that patients with APDS2 had decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%), and an increased frequency of transitional B cells (93%) ([@B11]). All four patients developed recurrent upper or lower respiratory tract infections and showed decreased serum IgG, which required intravenous immunoglobulin replacement therapy. Elevated serum IgM was observed in two patients, and one patient developed malignant lymphoma. Therefore, the four Japanese patients in the current study were considered to be typical cases of APDS2.

The former diagnoses of the four patients in the current study were HIGM (P2 and P4), CVID (P1), and IgG subclass deficiency (P3). Based on the phenotypic diversity and similarity in clinical and laboratory findings, considerable numbers of patients with APDS2, as well as patients with APDS1 ([@B13]), have been historically diagnosed as HIGM or CVID. From the first identification of APDS1 associated with hyperactive PI3K signaling, a definitive diagnosis of APDSs is performed by the identification of mutations in *PIK3CD* or *PIK3R1*. In addition to these genetic tests, the detection of enhanced pAKT signaling in T-cell blasts by functional assays has been used to confirm hyperactive PI3K signaling. However, this assay method is not suitable for rapid diagnosis, because it requires the cultivation of T cells. In the current study, we observed significantly higher levels of pAKT in CD19^+^ B cells, but not CD3^+^ T cells, CD16^+^CD56^+^ NK cells, or CD14^+^ monocytes isolated from fresh PBMCs from APDSs and APDS-L patients. The enhancement of pAKT in CD19^+^ B cells was pronounced in CD10^+^CD19^+^ immature B cells. Moreover, when we focused on this CD10^+^CD19^+^ B-cell population, there was no overlap in the value of ΔMFI of pAKT between APDSs or APDS-L patients and the other populations, including healthy controls and patients with CVID or HIGM. We also made a similar observation using cryopreserved PBMCs from patients with APDSs or APDS-L. This finding allowed us to perform the rapid detection of hyperactive PI3K signaling without culturing patient cells. Although further studies are required to optimize and evaluate this flow-cytometry-based assay system, this assay system has a potential to enable a rapid diagnosis of APDSs and APDS-L

In this study, the enhanced ΔMFI of pAKT in CD19^+^ B cells was a common finding among patients with APDSs or APDS-L. This observation was further enhanced if we focused on CD10^+^CD19^+^ immature B cells. These observations may reflect the importance of PI3K signaling in class-switch recombination in B cells ([@B9], [@B14]), and be related to abnormalities in the developmental stages of B cells, such as abnormalities of the germinal center structure ([@B11], [@B15]--[@B17]), increased circulating transitional B cells, and decreased class switching B cells in patients with APDSs ([@B1]--[@B4]). Curiously, the ΔMFI of pAKT was the highest in CD19^+^ B cells from APDS2 patients and was the lowest in CD19^+^ B cells from APDS-L patients. It is interesting to speculate possible molecular mechanism underlie this observation. The p85α is known to enhance enzymatic activity of PTEN ([@B18]). Although PTEN protein expression is normal in APDS2 patients ([@B2]), its enzymatic activity might be affected by functional impairment of p85α. Therefore, impairment of p85α may enhance pAKT by losing its inhibitory role of p110δ and its enhancing effect against PTEN enzymatic activity.

Relatively mild enhancement of pAKT in APDS-L patients might explain the clinical observation that only a part of patients with PHTS, caused by heterozygous mutations in PTEN, present with antibody deficiency ([@B5]). Indeed, the clinical penetrance of APDS-L is not high in patients with PHTS ([@B19]). There are considerable overlaps in the clinical manifestations between APDS1 and APDS2 (Table [1](#T1){ref-type="table"}) ([@B1]--[@B4], [@B11], [@B20]); however, there are also some differences in these two disorders. Indeed, patients with APDS2 have a higher susceptibility to lymphoma than patients with APDS1 ([@B11], [@B20], [@B21]) (Okano et al., under revision). The clinical penetrance of APDS1 is quite high, but not complete, possibly explaining the existence of asymptomatic carriers or cases with mild symptoms that only show recurrent respiratory infections and diagnosed as APDS1 by familial studies that identified a proband case ([@B20]). However, to date no asymptomatic carriers have been reported in patients with APDS2. Although we require large cohort studies to make strong conclusions, these clinical observations might be partially explained by the difference in elevated ΔMFI of pAKT. Further studies are necessary to understand the role of elevated ΔMFI of pAKT in CD19^+^ B cells on the immunological manifestations among patients with APDSs and APDS-L. The selective effect of pAKT in B cells (transitional B cells in particular), which may provide a detailed pathological mechanism of APDSs and APDS-L, remains to be explained.

###### 

Clinical features of patients with APDSs, APDS-L, or CVID.

  Clinical feature           APDS1 (%)   APDS2 (%)   APDS-L (%)       CVID (%)
  -------------------------- ----------- ----------- ---------------- ----------
  Pneumonia                  85          71          50               32--77
  Lymphoproliferation        75          89          44               N.D.
  Splenomegaly               58          43          N.D.             15--30
  Enteropathy                25          24          N.D.             9
  Granuloma                  0           N.D.        N.D.             8--9
  Meningitis/encephalitis    1.9         N.D.        N.D              3--4
  Autoimmunity               42          17          N.D.             22--29
  Malignancy                 13          28          22               3--8
  Neurodevelopmental delay   19          31          50               N.D.
  IVIG therapy               77          89          19               80
  Reference                  ([@B20])    ([@B11])    ([@B5], [@B6])   ([@B20])

Recently, molecular targeting therapy using an mTOR inhibitor was also effective for the treatment of lymphoproliferation in patients with APDSs ([@B1], [@B3], [@B11]). Therefore, the prompt and appropriate diagnosis of APDSs definitely benefits patients by providing a therapeutic choice of target therapy. The flow-cytometry-based rapid assay of PI3K activity described here has the potential to provide a rapid diagnosis of APDSs and APDS-L.

Concluding Remarks {#S5}
==================

The flow-cytometry-based rapid assay of PI3K activity described here provides a rapid discrimination assay of identified mutations in *PIK3CD, PIK3R1*, and *PTEN*, and might also be a potential diagnostic tool for patients with APDSs or APDS-L.
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APDS, activated PI3Kδ syndrome; APDS1, activated PI3Kδ syndrome 1; APDS2, activated PI3Kδ syndrome 2; APDS-L, activated PI3Kδ syndrome like immunodeficiency; APDSs, activated PI3Kδ syndrome 1 and activated PI3Kδ syndrome 2; AUC, area under the curve; cDNA, complementary DNA; CI, confidence interval; CMV, cytomegalovirus; CVID, common variable immunodeficiency; ΔMFI, difference in mean fluorescence intensity; EZR, Easy R; EBV, Epstein Barr virus; GOF, gain of function; HIGM, hyper IgM syndrome; IVIG, intravenous immunoglobulin; LOF, loss of function; MFI, mean fluorescence intensity; mTOR, mechanistic target of rapamycin; NK, natural killer; PBMCs, peripheral blood mononuclear cells; PCR, polymerase chain reaction; PI3K, phosphoinositide 3-kinase; PID, primary immunodeficiency syndrome; PIP2, phosphatidylinositol 3, 4- triphosphate; PIP3, phosphatidylinositol 3, 4, 5- triphosphate; PHTS, PTEN Hamartoma Tumor Syndromes; PTEN, phosphatase and tensin homolog; ROC, receiver operating characteristic; Ser473, Serine473; pAKT, AKT phosphorylation.
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